Pluristem Therapeutics Inc. changes its name to “Pluri


  • From July 26, 2022, Multipleit is Stock will trade under the symbol MORE
  • The new name reflects the companyit is strategy for take advantage of its innovative 3D cell-based technology to a range of areas, developing cell-based products that address various life challengesall in promoteing global well-being and sustainability
  • Visit our New Company website: www.pluri-biotech.com

HAIFA, Israel, July 25. 12, 2022 (GLOBE NEWSWIRE) — Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, today announced that it is changing its name (from Pluristem Therapeutics Inc. Nasdaq: PSTI), reflecting a broader strategy of leveraging its 3D cell expansion technology to develop innovative cell-based products that can be leveraged for a range of fields beyond medicine , providing solutions for various fields of life sciences. Effective July 26, 2022, Pluri will begin trading on the Nasdaq under the new ticker symbol “PLUR”, CUSIP number 72942G 104.

Pluri’s technology will continue to fuel medical research and develop pharmaceuticals, while also being used to potentially create new cellular solutions for other innovative initiatives, such as food technology, agricultural technology and biologics. , either independently or through partnerships, to drive overall well-being and sustainability.

“We believe there is a huge need across many industries for a cell-based development platform that delivers quality and accuracy while being efficient, scalable, cost-effective, and consistent from batch to batch. Pluri’s technology delivers all of these features and more,” said Pluri CEO and President Yaky Yanay. “After nearly two decades as Pluristem, we are proud to grow as Pluri, leveraging our breakthrough technology to increase our market share in multiple verticals. As the connecting arch of our new logo suggests, it’s time for Pluri to move from this single point to next-generation products in a range of areas.

Pluri’s first collaboration, based on its innovative 3D cell-based technology platform, was formed in January 2022 to produce sustainably grown foods with Israeli food giant Tnuva Group.

The company intends to continue bringing technology to life, creating next-generation cell-based products that improve human well-being, increase environmental sustainability and advance solutions to the challenges of the future.

“Our goal is to turn cells into solutions that make the world a better place,” Yanay said. “Increasing our business across multiple verticals means we can do even more to improve human life and contribute to a more sustainable planet. We seek to solve our planet’s biggest and most pressing problems starting with the smallest unit of any organism: a single cell.

For more information, visit our new website at: www.pluri-biotech.com

About Multiple Inc.

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is at the forefront of a biotechnology revolution that advances wellness and sustainability globally. . The Company’s technology platform, a patented and validated state-of-the-art 3D cellular expansion system, provides novel cellular solutions for a range of initiatives, from medicine and climate change to food scarcity, cruelty to animals and beyond. Pluri’s method is highly accurate, scalable, cost effective and consistent from batch to batch. Pluri currently operates in regenerative medicine and food technology and aims to build partnerships that leverage the company’s 3D cell technology for other industries that require efficient mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.

Safe Harbor Statement

This press release contains express or implied forward-looking statements under the Private Securities Litigation Reform Act of 1995 and other United States federal securities laws. For example, Pluri uses forward-looking statements when discussing plans for future product development, its marketing activities, market opportunities for the company’s products, and the potential for the company’s products and solutions to enhance the well -being human, increasing environmental sustainability and advancing solutions to future challenges. These forward-looking statements and their implications are based on the current expectations of Pluri’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements regarding Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in initiating and/or completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it evolves and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products could end up being more expensive than expected; laboratory results may not translate to as good results under real clinical conditions; his patents may not be sufficient; its products may harm recipients or consumers; changes in legislation having a negative impact; failure to develop and introduce new technologies, products and applications on a timely basis; loss of market share and pricing pressure resulting from competition, which could cause Pluri’s actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unforeseen events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.

Media Contacts

Investors: [email protected]

Israeli media: Shachar Yental at [email protected]

US Media: Nathan Miller at [email protected] / Tara DiMaio at [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/831a0fa9-5907-46e3-b0c2-6b64b15cbf6f

Previous Athletes brave extreme temperatures as heat wave shortens New York triathlon
Next Poorer countries could suffer from US efforts to slow inflation